Expanded Access Policy

Intellia is committed to solving the complex challenges of making CRISPR-based therapies a reality for patients suffering with severe and life-threatening genetic diseases, including diseases such as transthyretin (ATTR) amyloidosis, hereditary angioedema (HAE) and acute myeloid leukemia (AML). In these efforts, Intellia is guided by ethical, scientific and legal principles, which require well-designed and controlled clinical trials to evaluate the safety and efficacy of our potential investigational genome editing therapies. Click here to visit the National Institutes of Health (NIH) website to learn more about clinical trials and how they work.

Under certain circumstances, a person suffering a serious or life-threatening disease may ask to use an experimental treatment outside a clinical trial before its safety and efficacy have been fully evaluated, and before the regulatory authorities have approved it. Generally, this is an option only for patients who have exhausted all available medical options and do not qualify for the ongoing clinical trials. The U.S. Food and Drug Administration (FDA) explains such “expanded access” as follows:

Expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Intellia appreciates the intent of expanded access programs but, at this time, we can best advance the development of these potential promising products by enrolling patients in clinical trials. Our clinical trials will be designed, conducted and monitored to ensure that the safety and effectiveness of our experimental therapies are properly evaluated before they are made available generally. Should you have any questions, please reach out to [email protected] or speak with your physician. Intellia expects to acknowledge receipt of requests sent to this email address within five business days.

As authorized by and in accordance with the 21st Century Cures Act, Intellia reserves the right to revise this policy at any time.